Web Research
The Bottom Line from the Web
The web adds one important point that filings alone do not fully surface: Cigna is no longer facing abstract PBM regulation risk, because Express Scripts settled the FTC insulin case and federal PBM transparency rules are moving directly into contract economics. That pressure is arriving while Cigna is executing well near term, with Q1 2026 adjusted EPS of $7.79 and guidance raised to at least $30.35, so the underwriting question is whether Evernorth can protect margins as rebates, spread pricing, and large-client contract terms reset.
FTC Settlement Estimated Patient Savings
Q1 2026 Adjusted EPS
2026 Adjusted EPS Floor
Average Analyst Target
What Matters Most
1. PBM regulation is now a concrete Evernorth margin test.
The FTC settlement with Express Scripts requires material business-practice changes, including more transparency, lower patient costs, and ongoing oversight. Reuters reported the settlement requires Express Scripts to work with local pharmacies, disclose drug costs to employers annually, move Ascent Health Services to the United States, and count certain direct drug purchases toward deductibles; the FTC case page says the settlement could lower patient out-of-pocket costs by up to $7 billion over 10 years. Sources: Reuters, FTC, Federal Register.
2. Federal PBM reforms target the same profit mechanics.
The 2026 appropriations reforms delink Medicare Part D PBM compensation from list prices and rebates, require 100% pass-through of rebates and related remuneration to payers, and expand reporting on spread pricing, formulary placement, and affiliated-pharmacy incentives. The direct near-term impact is Medicare Part D, but the investor issue is broader because employers can use the same transparency template when renegotiating commercial PBM contracts. Sources: AJMC, KFF, Congress.gov.
3. Cigna is trying to turn reform into a product transition, not just compliance.
Evernorth announced a rebate-free pharmacy benefit model that promises average monthly brand-drug cost reductions of about 30% for full-price payers, adoption by Cigna Healthcare fully insured lives in 2027, and standard availability for Evernorth pharmacy clients in 2028. The positive case is that Cigna has been preparing for the rule change; the risk is that client adoption, administrative-fee recapture, and specialty-drug treatment determine whether margin is preserved. Sources: Evernorth announcement via StockTitan, Drug Channels analysis, Managed Healthcare Executive.
4. Q1 2026 execution was strong, but the pharmacy benefit segment already shows pressure.
Cigna reported Q1 2026 revenue of about $68.5 billion, adjusted EPS of $7.79, and raised the full-year adjusted EPS outlook to at least $30.35. The same quarter showed Evernorth Pharmacy Benefit Services pretax adjusted earnings down 28%, consistent with client renewals and transition investments, which makes the quality of the Q1 beat more nuanced than the headline. Sources: company newsroom, Q1 transcript summary, Morningstar quote page.
5. The CEO handoff is well planned, but it lands during a major PBM pivot.
Brian Evanko becomes CEO on July 1, 2026, with David Cordani moving to Executive Chair. CNBC reported that the announcement surprised at least two analysts and the stock fell more than 5%, though analysts also framed Evanko as a natural successor with broad Cigna operating experience. Sources: CNBC, company succession announcement, proxy summary.
6. Portfolio reshaping is accelerating: ACA exit and eviCore review.
Cigna will exit the Affordable Care Act individual exchange business after the 2026 plan year, affecting about 369,000 members across 11 states, and management is reviewing strategic alternatives for eviCore. This reduces exposure to a shrinking, subsidy-sensitive market, but it also flags that Cigna is prioritizing scale and margin over broad member growth. Sources: Forbes, STAT, Q1 transcript.
7. Scale remains a moat, but client concentration is no longer a footnote.
Express Scripts claimed the top PBM spot again in 2025 with 2.22 billion adjusted prescription claims, up 4.8%, while the Big Three PBMs processed about 80% of equivalent prescription claims. At the same time, Cigna disclosed that one pharmacy benefit client represented about 19% of 2025 external revenue, and outside analysis attributes some Express Scripts growth to Centene, Prime Therapeutics, and Department of Defense relationships that can demand better economics. Sources: Drug Channels 2025 PBM share, Cigna 10-K summary, PitchBook profile excerpt.
8. Legal risk broadened from regulation to private litigation.
A February 17, 2026 racketeering class action was filed against Express Scripts and Cigna-related entities, alleging that rebate flows through Ascent harmed plan sponsors; the class has not been certified and the claims remain allegations. This matters because it creates a private-law counterpart to the FTC settlement and could shape employer negotiating posture even before any court outcome. Sources: Lawdragon press release, Health Care Uncovered summary, Federal Register consent-order analysis.
9. Analysts are constructive after Q1, despite the regulatory overhang.
Consensus remains positive: WSJ/Barrons data show 19 Buy, 5 Overweight, and 3 Hold ratings, with no Underweight or Sell ratings and an average target near $342. MarketScreener also listed post-Q1 target increases from Bernstein to $371, Goldman Sachs to $340, Barclays to $310, Baird to $337, and Mizuho to $330. Those targets show sentiment, not proof that Evernorth margin risk is resolved. Sources: WSJ research ratings, Barrons research ratings, MarketScreener consensus.
Recent News Timeline
What the Specialists Asked
Governance and People Signals
The governance signal is a planned handoff, not an emergency turnover: Evanko becomes CEO on July 1, 2026, Cordani becomes Executive Chair, and the proxy summary describes a multi-year succession process. The risk is timing, because the handoff coincides with the FTC settlement, federal PBM reforms, and execution of the Signature pharmacy model. Sources: company announcement, CNBC, proxy summary.
Compensation is meaningful but not obviously detached from performance. A proxy-data summary states that about 92% of 2025 CEO target pay was at risk, 77% was long-term equity, and the 2023-2025 strategic performance share cycle paid 73% of target, which suggests some downside when performance goals are not fully met. Source: proxy summary.
The insider signal is mixed rather than clearly bearish. March 2026 sales by Jones and Neville are worth monitoring, but Cordani bought nearly $1.0 million in November 2025 and the available web evidence does not show a broad 2026 executive exit pattern.
Industry Context
The industry evidence is unusually direct: Cigna has scale in a concentrated PBM market, but the same concentration is exactly what regulators, employers, pharmacies, and plaintiffs are attacking. The Big Three PBMs still process about 80% of equivalent prescription claims, and Express Scripts remained the largest by 2025 adjusted claim volume; that moat supports procurement and claims-processing scale, but it also gives large clients and regulators leverage to demand explicit pricing.
Big Three PBM Claim Share
Express Scripts 2025 Claims
Express Scripts Claim Growth
Single PBM Client Revenue Share
Drug Channels estimated Express Scripts handled 2.22 billion adjusted prescription claims in 2025, up 4.8%, while the three largest PBMs processed about 80% of equivalent claims. The same research notes growth was helped by large client relationships, and Cigna filings show one pharmacy benefit client represented about 19% of 2025 external revenue, making client economics the key durability test. Sources: Drug Channels, Cigna 10-K summary.
Employer behavior also cuts both ways. HR Brew found many employers are interested in alternatives but switching away from Big Three PBMs remains operationally difficult; that supports retention, but it also means any successful transparent model from a large incumbent can reset the market faster than a small challenger could. Source: HR Brew.
The peer scale snapshot reinforces Cigna's middle position in managed care: not UnitedHealth-sized, but with larger market value than Humana and Centene and a PBM/specialty mix that gives it a different risk profile than payer-heavy peers. Sources: UNH, CVS, ELV, HUM, CNC.